Detailed Information on Publication Record
2019
Radiofrequency ablation in pancreatic cancer
HLAVSA, Jan, Vladimír PROCHÁZKA, Tomáš ANDRAŠINA, Tomáš PAVLÍK, Igor PENKA et. al.Basic information
Original name
Radiofrequency ablation in pancreatic cancer
Authors
HLAVSA, Jan (203 Czech Republic, guarantor, belonging to the institution), Vladimír PROCHÁZKA (203 Czech Republic, belonging to the institution), Tomáš ANDRAŠINA (703 Slovakia, belonging to the institution), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Igor PENKA (203 Czech Republic, belonging to the institution) and Zdeněk KALA (203 Czech Republic, belonging to the institution)
Edition
Rozhledy v chirurgii, Česká chirurgická společnost ČLS JEP, 2019, 0035-9351
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30212 Surgery
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
RIV identification code
RIV/00216224:14110/19:00108593
Organization unit
Faculty of Medicine
Keywords in English
pancreas; cancer; radiofrequency ablation
Tags
International impact, Reviewed
Změněno: 25/9/2020 09:14, Mgr. Tereza Miškechová
Abstract
V originále
Introduction: Clinical study evaluating the impact of intraoperative radiofrequency ablation in pancreatic cancer. Methods: Patients with histologically proved pancreatic cancer were included. Two groups were defined. In the RFA group (n=24) intraoperative RFA of the pancreatic tumour was performed. In the control group (n=24) only the bypass procedure was indicated (gastroenteric and hepaticojejunal anastomosis). No patient received neoadjuvant chemotherapy. Three-month morbidity and mortality, overall survival, quality of life, pain relief and radiological response were studied. Results: Overall three-month morbidity and mortality were 41.7% and 8.3%, respectively. RFA related morbidity and mortality reached 16.6% and 8.3%, respectively. The overall median survival time was 9.9 and 8.3 months in the RFA group and in the control group, respectively. The survival difference was not of statistical significance (p=0.758). QoL improvement after RFA was not proved. There was no statistically significant analgesic effect of RFA. Postoperative CT scan assessed as per RECIST criteria displayed progressive disease, stable disease, partial response and complete response in 41.6%, 45.8%, 8.3% and 0% cases, respectively. Conclusion: Intraoperative RFA of locally advanced and metastatic pancreatic cancer is a feasible palliative method. A survival benefit of this method remains doubtful, even though some positive results have been achieved in patients with localized, well-differentiated tumours. Although RFA was not associated with any impairment of the quality of life, no convincing evidence of a positive impact thereof on QoL was shown, either, during the three-month postoperative period. Pain relief was not achieved during the first 3 months after RFA.
Links
| NV16-31314A, research and development project |
|